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Iron uptake and ferrokinetics in healthy male
subjects of an iron-based oral phosphate binder
(SBR759) labeled with the stable isotope 58Fe
Hans-Peter Gschwind,*a Dietmar G. Schmid,a Friedhelm von Blanckenburg,†b
Marcus Oelze,†b Kirsten van Zuilen,‡b Alan J. Slade,c Sylvie Stitah,d
Daniel Kaufmanne and Piet Swarta
SBR759 is a novel polynuclear iron(III) oxide–hydroxide starchsucrosecarbonate complex being developed
for oral use in chronic kidney disease (CKD) patients with hyperphosphatemia on hemodialysis. SBR759 binds
inorganic phosphate released by food uptake and digestion in the gastro-intestinal tract increasing the fecal
excretion of phosphate with concomitant reduction of serum phosphate concentrations. Considering the
high content of B20% w/w covalently bound iron in SBR759 and expected chronic administration to
patients, absorption of small amounts of iron released from the drug substance could result in potential iron
overload and toxicity. In a mechanistic iron uptake study, 12 healthy male subjects (receiving comparable
low phosphorus-containing meal typical for CKD patients: r1000 mg phosphate per day) were treated with
12 g (divided in 3  4 g) of stable 58Fe isotope-labeled SBR759. The ferrokinetics of [58Fe]SBR759-related
total iron was followed in blood (over 3 weeks) and in plasma (over 26 hours) by analyzing with high
precision the isotope ratios of the natural iron isotopes 58Fe, 57Fe, 56Fe and 54Fe by multi-collector inductively
coupled mass spectrometry (MC-ICP-MS). Three weeks following dosing, the subjects cumulatively absorbed
on average 7.8  3.2 mg (3.8–13.9 mg) iron corresponding to 0.30  0.12% (0.15–0.54%) SBR759-related
iron which amounts to approx. 5-fold the basal daily iron absorption of 1–2 mg in humans. SBR759 was well-
tolerated and there was no serious adverse event and no clinically significant changes in the iron indices
hemoglobin, hematocrit, ferritin concentration and transferrin saturation.
1 Introduction
Serum phosphate homeostasis is primarily regulated by the
body’s ability to excrete excess dietary phosphate via the kidneys.
Patients with chronic renal insuﬃciency, who have varying
degrees of renal function, accumulate excess phosphate resulting
in a condition known as hyperphosphatemia. First generation,
calcium- or aluminum-containing phosphate binders are eﬀec-
tive in reducing the absorption of phosphate from the diet, but
require large doses and may result in accumulation of calcium
or aluminum. Intense research eﬀorts have led to the develop-
ment of a second generation of potent, calcium and aluminum-
free, phosphate binders such as sevelamer hydrochloride (HCl)
(RenaGels), a cross-linked poly-allylamine hydrochloride (Bleyer,
1999)1 or fosrenolt, a lanthanum carbonate compound (D’Haese,
2003).2 While sevelamer-HCl has proven eﬃcacy it is associated
with possible induction of metabolic acidosis and gastrointestinal
(GI) side eﬀects (Brezina, 2004).3 In addition, sevelamer-HCl does
not bind phosphate eﬃciently in an acidic environment. Lantha-
num carbonate also demonstrates significant phosphate-binding
properties and good eﬃcacy but has also been associated with
hypercalcemia (Hutchison, 2009)4 (Hutchison, 2005)5 (D’Haese,
2003).2 Studies in both rats (Slatopolsky, 2005)6 and humans
(Spasovski, 2006)7 have suggested that long-term lanthanum
administration carries the risk of blood and tissue accumulation.
SBR759 is a novel polynuclear iron(III) oxide–hydroxidestarch–
sucrosecarbonate complex designed for oral use to specifically
bind with high affinity and excrete inorganic phosphate. SBR759
is an odorless, water-insoluble, slightly sweet tasting powder
formulation. The compound was developed with SeBo GmbH,
Germany for the treatment of hyperphosphatemia commonly
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observed in patients with CKD. SBR759 has been shown to be an
effective phosphate binder in vivo and shows rapid, selective, and
high in vitro binding of phosphate at both highly acidic and
neutral pH with phosphate-binding capacity similar to currently
available agents (Hergesell, 1999)8a (Hergesell, 1999).8b SBR759
lowered serum phosphate concentrations rapidly and to a clini-
cally meaningful extent across a wide dose range with good
tolerability (Block, 2010).9 In phase II dose titration studies
assessing Asian patients requiring hemodialysis, SBR759 demon-
strated superior efficacy in phosphate control compared with
sevelamer-HCl, an approved phosphate binder (Chen, 2011)10
(Fukagawa, 2014).11
SBR759 is a chemical complex of polymeric nature. It is a novel
member of the iron-oxide–hydroxide compound class, which is
different from previously described iron-oxide–hydroxides such as
goethite, akagane´ite or lepidocrocite. Even though it resembles
ferrihydrite in its characteristics, it is different to ferrihydrite and
known iron-oxides–hydroxides as follows: (i) sucrose, carbonate
and very likely starch are included in the coordination sphere of
the iron atoms and bound to the iron atoms by a coordinative
bond; (ii) Mo¨ssbauer spectroscopy showed that SBR759 is different
to standard iron(III)-oxides. Thus, it can be described formally as
the polynuclear iron(III) oxide–hydroxidestarchsucrosecarbonate
complex and is therefore not a simple mixture of these starting
materials. Phosphate binding by SBR759 is accomplished by a
ligand exchange mechanism displacing sucrose carbonate or
hydroxyl groups, the latter similar to the iron(III) oxide–hydroxide
complex described in (Sigg, 1980)12 forming predominantly binuc-
lear bidentate complexes (Parfitt, 1975).13 The iron in SBR759 is
covalently bound to the starch–saccarose complex and is very
stable against digestion in the human gastro-intestinal tract
(GIT). However, due to the high iron content (B20% w/w) of
SBR759 and gram quantity doses required for treatment, chronic
administration may be accompanied by absorption of iron,
released from the iron(III) complex. With chronic treatment often
required in patients with chronic kidney disease, absorption of
this exogenous iron may result in the potential for iron overload
and toxicity. Iron toxicity results when free iron not bound to
transferrin (NTBI) appears in the blood, forming labile plasma iron
(LPI) and catalyzing the generation of reactive oxygen species (ROS)
(Anderson, 2007)14 that can damage tissues. Likewise, generation
of ROS in the gut for prolonged periods of time could lead to
epithelial cell damage and may facilitate pathogen entry to the
organism (Cha´vez, 2007).15 In vitro tests have shown that the iron
oxides present in SBR759 are not redox-active, a prerequisite for
the above mentioned side effects (Novartis, unpublished data).
Nonclinical testing with 59Fe-radiolabeled SBR759 in dogs
demonstrated that less than 0.2% of the SBR759-related iron
dose was absorbed (Novartis, unpublished data). In order to
gain insight into the ferrokinetics and to quantify the extent of
SBR759-related iron absorption following oral administration
of SBR759, a phase I clinical study with stable 58Fe isotope-
labeled SBR759 in healthy male subjects was performed. The
ferrokinetics of [58Fe]SBR759-related total iron was followed in
whole blood (over 3 weeks) and in plasma (over 26 hours)
by analyzing the isotope ratios of the natural iron isotopes by
MC-ICP-MS. Apart from whole blood, plasma was chosen
because it comprises a more dynamic compartment concerning
the turnover of transferrin-bound iron as compared to red
blood cells which are characterized by a 120 day erythrocyte
life span in circulation (Walczyk, 2005).16 Aside from tracing
the ferrokinetics and the extent of the oral absorption of
[58Fe]SBR759-related iron in blood and plasma determined
upon changing 58Fe/56Fe-isotope ratios, a possible diﬀerence
in the 56Fe/54Fe isotope signature between erythrocytes (whole
blood) and plasma was measured by MC-ICP-MS in samples
collected between 0 and 26 hours post first SBR759 dose. These
results are presented in a companion paper that also contains
the measured iron concentrations and iron isotope ratio data
used for the present study in an Online Supplement S4 (von
Blanckenburg, submitted).17 This study also provided insight
into the applicability of the MC-ICP-MS technique in measuring
isotope-labeled iron in human blood and plasma.
2 Materials and methods
2.1 Selecting iron isotopes to investigate iron uptake in
human
Biomarkers such as transferrin concentration and ferritin
saturation can be used as clinical indicators as well as the state
of iron stores including iron overload. Direct quantification of
ferrokinetics was typically obtained through the use of isotope
labeled iron compounds. Applying radioactive iron isotopes
such as 59Fe is a very sensitive and a specific approach, but it
presents several disadvantages: (1) the radioisotopes 59Fe and
55Fe decay via X- and/or b-ray emission with physical half-lives
of 45 days and 2.7 years, respectively; (2) absorbed iron is not
actively excreted from and is salvaged in the human body
during hematopoiesis (red blood cell production) which raises
ethical concerns exposing human subjects to radioactivity over
a long time; (3) formation of unknown impurities due to radio-
lysis of the drug and therefore radiochemical stability might not
be determinable; (4) this is in particular the case for SBR759
which is generally insoluble and has a very complex molecular
structure; (5) radiation during the Good Manufacturing Practice
(GMP) production of the drug, shipping, administration and
analysis requires special precautions, facilities and handling
procedures to minimize exposure to radioactivity and cross-
contamination; (6) the short physical half-life of 45 days of
59Fe does not simply allow prolonged synthesis processes under
GMP production or keeping retained samples for analysis after-
wards; (7) factors contributing to measurement variability have
to be minimized as much as possible, and therefore, it is
essential that the drug product is labeled homogeneously with
the iron isotope by applying GMP production which is extremely
diﬃcult to achieve using radioactive iron.
The disadvantages mentioned above can be circumvented
by applying the isotope dilution concept using stable iron
isotopes, e.g. 58Fe or 57Fe and determination of isotope ratios
by MC-ICP-MS. Many clinical iron uptake studies were conducted
in the past using stable iron isotopes and applying the isotope
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dilution concept, mainly in nutrition research in adults (Whittaker,
1989)18 (Barrett, 1992)19 and children (Janghorbani, 1986)20
(Fomon, 1988)21 (Fomon, 1989)22 (Woodhead, 1988)23 (Walczyk,
1997)24 (Vasquez Garibay, 2001).25
2.1.1 Selection of a stable iron isotope label and the degree
of labeling. Due to its very low abundance in nature (B0.3%),
the stable iron isotope 58Fe was chosen to label SBR759,
expecting a high sensitivity and a low detection limit of the
isotopic label. With the development of highly sensitive
MC-ICP-MS instruments (Halliday, 1998),26 (Jakubowski,
2011)27 a low isotope enrichment can be applied. We estimated
that additional enrichment of SBR759 with approx. 2.5% 58Fe
would be suﬃcient to detect changes in the 58Fe/56Fe ratio by
MC-ICP-MS with a good signal-to-noise ratio and high precision
and accuracy in blood and plasma. Low isotope enrichment
reduces: (i) the costs for the total amount of iron isotope
needed to produce the drug product, and (ii) the potential of
introducing associated heavy metal impurities which may lead
to possible toxicity.
2.2 Study design
The clinical part of this open-label study was performed at
Covance Clinical Research Unit AG (former Swiss Pharma
Contract Ltd), Allschwil, Switzerland. This study was approved
by the Cantonal Ethics Committee and was conducted in accor-
dance with the declaration of Helsinki (1964 and subsequent
revisions) and International Conference on Harmonization-
Good Clinical Practice guidelines. The analytical investigations
of the ferrokinetics and iron uptake of [58Fe]SBR759-related iron
were not required to be conducted under GLP but were carried
out according to the available current scientific standards.
2.2.1 Subjects. Twelve (12) healthy male volunteers were
enrolled and completed the study (Table 1). All subjects gave
written informed consent before participating in the study. Each
subject participated in a 21 day screening period (Day-21 to Day-2),
a baseline period (Day-1), and a 12 hour dosing period (Day 1,
three administrations of 4 g of [58Fe]SBR759 each) followed by a
3 week ambulatory period and a study completion on Day 21.
Healthy, nonsmoking men between 18 and 45 years of age were
enrolled. Subjects with (i) hematocrito41%, (ii) hemoglobino13.8
or 417.2 g dL1, (iii) serum ferritin o20 or 4320 ng mL1,
(iv) transferrin saturation o20%, (v) reticulocyte count 41.5% or
platelets o100000 mL1, (vi) history of anemia, hemochroma-
tosis or other dyscrasia(s), e.g. thalassemia, myelodysplastic
syndrome, etc., treated or not had to be excluded from the study.
A total of 12, iron replete i.e., nonanemic, subjects were
recruited. This population was selected as their propensity for
iron absorption was expected to be similar to that of a CKD
patient on dialysis based on similarities in absorption of thera-
peutic iron salts (Skikne, 2000).28
2.2.2 Study drug
Stable 58Fe isotope labeling of SBR759. Research grade
58Fe-enriched (99.49%) iron was purchased from Isoflex, San
Francisco, CA, USA. 58Fe was completely dissolved in 37% (w/w)
aqueous hydrochloric acid at ambient temperature. The resulting
aqueous FeCl2-solution was filtered and subsequently oxidized by
addition of excess of gaseous chlorine. The resulting aqueous
58FeCl3 solution was evaporated to dryness yielding
58FeCl36H2O
as colorless hygroscopic powder (Tessenderlo AG, Bad Zurzach,
Switzerland). 58FeCl36H2O was diluted with commercially available
FeCl36H2O (Merck, Darmstadt, Germany) to a target 58Fe content of
2.5%. 58Fe stable isotope-labeled SBR759was prepared starting from
58Fe-stable isotope-labeled FeCl36H2O using the same synthesis
protocol as for the GMP production of the SBR759 drug substance
for human use (Novartis Pharma, AG; Basel, Switzerland).
The drug product (SBR759 58Fe Moda Saccharose, iron aqua
carbonate hydroxyl-oxo starch sucrose complex (CAS registra-
tion No: 1041180-02-2)) contained 20.4% w/w of iron consisting
of 5.706% 54Fe, 89.552% 56Fe, 2.077% 57Fe and 2.665% 58Fe
isotopes as determined by MC-ICP-MS.
Table 1 Demographic data, administered [58Fe]SBR759 dose and the total amount of iron in whole blood of each subject at pre-dose (baseline)
Subject
number
Total [58Fe]SBR759
dose (g)
Body
weight (kg)
Body
height (cm)
Total Fe concentration in whole blooda,b
Calculated blood
volumec (mL)
Total amount of Fe
in whole blood (mg)(ppm) (mg mL1)
5101 12.47 71.7 174 460 483 4400 2127
5102 12.48 97.8 177 490 515 5320 2735
5103 12.47 86.8 172 450 473 4820 2282
5104 12.49 84.9 179 470 494 4960 2450
5105 12.45 57.2 165 500 525 3690 1937
5106 12.48 78.0 186 460 483 4950 2389
5107 12.42 79.5 182 460 483 4880 2357
5108 12.47 59.2 166 460 483 3780 1827
5109 12.47 67.2 179 450 473 4410 2084
5110 12.46 102.1 186 490 515 5710 2939
5111 12.47 97.4 183 510 536 5470 2934
5112 12.46 81.1 180 510 536 4870 2612
Mean 12.47 80.2 177 475.8 499.9 4770 2389
SD 0.017 14.7 7.0 22.7 24.0 620 365
CV (%) 0.13 18.3 3.9 4.8 4.8 13.0 15.3
Range 12.42–12.49 57.2–102.1 165–186 450–510 473–536 3690–5710 1827–2939
a As determined by ICP-OES in blood collected at 0 h (pre-dose, baseline). b Using a blood density of 1.050 g mL1 at 37 1C (Geigy Scientific
Tables).34 c Blood volume calculated according to eqn (12).
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The molar iron isotope ratios 58Fe/56Fe, 58Fe/54Fe, 57Fe/54Fe
and 56Fe/54Fe measured by MC-ICP-MS in the [58Fe]SBR759 drug
product are listed in Table 2 as relative to the ‘‘IRMM-014’’ iron
reference standard (IRMM-014 Fe Standard).29 The raw data are
reported in Online Supplement S4 (von Blanckenburg,
submitted).17
2.2.3 Drug administration. The study drug was provided as
open-label medication packaged in sachets each containing a
single dose of 4 grams of [58Fe]SBR759. Subjects received a total
daily dose of 12 g (mean  SD, n = 12: 12.47  0.017 g; Table 1)
which was given in three portions of approx. 4 g (range: 4.12–
4.17 g), each. Each portion of the study medication was
suspended in water and administered by the study center
personnel immediately after breakfast (0 h) after an overnight
fast of at least 10 hours, thereafter at lunch (4 h) and dinner
(10 h) on Day 1 of dosing. In order to better replicate the
expected clinical conditions in patients with CKD patients who
are generally prescribed a low phosphorus diet, the subjects in
this clinical trial received standardized low phosphorus meals
(r1000 mg phosphate) that excluded: red meat, beans,
spinach, citrus fruits or juices during the dosing day. The
subjects kept their usual diet habits when not domiciled.
2.2.4 Sample collection. Serial blood samples were collected
at 0 h (pre-dose; baseline), 6, 12, 16, 22 (Day 1), 26, 34 (Day 2), 106
(Day 5), 250 (Day 11), 322 (Day 14), and 490 h (Day 21) post
first dose.
In order to minimize hemolysis during Day 1 and Day 2
when several blood withdrawals took place, blood samples were
collected via a plastic cannula placed in a forearm vein that
remained through sampling 26 hours post last dose. For blood
sampling at Days 5, 11, 14 and 21 a metallic needle (venipuncture)
was used for individual samplings. Blood was collected (0–16 h:
35 mL; 22–490 h: 5 mL) via gentle aspiration into special 7.5 mL
S-Monovettess for metal analysis containing only a small and
specified amount of metal impurities (o50 ng iron per tube;
Sarstedt, Germany). These tubes contained about 4–7 mL of a
lithium heparin solution corresponding to about 0.1% of the final
blood sample volume. After blood collection the tubes were
inverted gently several times. Immediately after collection, five
aliquots of whole blood were exactly weighed into pre-labeled
polypropylene cryotubes and stored at r20 1C.
Plasma was obtained from heparinized blood (0, 6, 12, 16, 22
and 26 h post first dose) by centrifugation at 2000  g, at 4 1C
for 10 min. Plasma was recovered into pre-weighed tubes
(S-Monovettess for metal analysis, Sarstedt) and stored at
r20 1C. Plasma samples which displayed signs of hemolysis
were excluded from data analysis.
2.2.5 Sample storage and shipment conditions. After sample
collection, blood and plasma samples were frozen and stored at
r20 1C until and after analysis in the analytical laboratories.
Samples were shipped to analytical laboratories under dry ice to
keep them frozen.
2.2.6 Safety of subjects and drug tolerability assessments.
Safety of subjects and drug tolerability assessments involved
monitoring and recording of all adverse events (AEs) and
serious adverse events (SAEs), with their severity and relation-
ship to the study drug; regular monitoring of hematology,
blood chemistry; urinalysis; ECG; regular measurement of vital
signs; and the performance of physical examinations. The
subjects’ iron status was monitored by measuring hemoglobin,
hematocrit, ferritin and transferrin saturation (Table 3).
2.3 Iron isotope determination in blood and plasma
2.3.1 MC-ICP-MS. For stable iron isotope analysis by multi-
collector ICP-MS and the sample preparation required, we used
the protocol described by (Schoenberg, 2005).30 Detailed
modifications of that method and the new developments to
allow for measurements of stable iron isotopes in blood and
plasma are reported in a companion publication to this study
(von Blanckenburg, submitted).17 Briefly, iron extraction from
blood and plasma was achieved by microwave irradiation
Table 2 Molar iron isotope ratios of the [58Fe]SBR759 drug product
determined by MC-ICP-MS. The iron isotope ratios 58Fe/56Fe, 58Fe/54Fe,
57Fe/54Fe and 56Fe/54Fe were determined by MC-ICP-MS following eqn (1)
relative to the ‘‘IRMM-014’’ iron standard29
Iron isotope ratios
58Fe/56Fe 58Fe/54Fe 57Fe/54Fe 56Fe/54Fe
Iron isotope ratio 0.029761 0.46705 0.363943 15.69313
Relative error (2s; n = 3) 0.000034 0.00054 0.000012 0.00030
CV (%) 0.11 0.12 0.32 0.0019
Table 3 Iron toxicity-specific parameters hemoglobin, hematocrit, ferritin and transferrin saturation (TSAT) measured at screening, baseline and at Days
11 and 21 in blood of 12 healthy male subjects following treatment with an oral dose of 12 g (3  4 g) of [58Fe]SBR759
Mean  SD (range)
Iron toxicity-specific laboratory parameters
Hemoglobina (mmol L1) Hematocrit (%) Ferritin (mg L1) TSAT (%)
Screening (Day-21 to Day-2) 9.7  0.52 (9.0–10.6) 45.1  2.0 (42.5–49.8) 94.6  52.9 (30–217) 34.6  11.2 (20.8–54.6)
Baseline (Day-1) 9.4  0.48 (8.7–10.2) 44.0  2.3 (40.6–48.7) 86.4  56.4 (28–219) 35.8  19.0 (22.0–93.6b)
Day 11 8.9  0.65 (8.2–9.8) 41.9  2.4 (38.4–46.2) 70.5  43.6 (28–167) 24.3  8.9 (10.1–36.9)
Day 21 8.8  0.62 (8.0–10.1) 41.8  2.8 (37.0–47.9) 68.3  54.3 (30–191) 24.0  12.5 (10.5–45.2)
Lower Upper Lower Upper Lower Upper Lower Upper
Normal ranges 8.7 10.9 40.1 51 30 400 16 45
a To obtain g dL1 divide nmol L1 values by 0.6206. b Outlier value: not repeated nor excluded from average and standard deviation.
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treatment with subsequent ion exchange chromatography.
Isotope ratios were determined on a Thermo Finnigan ‘‘Neptune’’
Multicollector ICP-MS at the Institute for Mineralogy from the
Leibniz University of Hannover, Germany.
Iron standard for controlling MC-ICP-MS measurements. Com-
mercially available ‘‘IRMM-014’’ iron reference material (from
EU Institute for Reference Materials and Measurements, Geel,
Belgium) was used as the ‘‘bracketing standard’’ in measure-
ments (Schoenberg, 2005),30 and to calculate normalized
isotope ratio diﬀerences according to (eqn (1)). Iron in the
‘‘IRMM-014’’ standard is reported to be at a molar weight of
55.84515  0.00048 g mol1 consisting of the following isotope
mass fractions: 54Fe = 5.845%, 56Fe = 91.754%, 57Fe = 2.1192%
and 58Fe = 0.2818%. For MC-ICP-MS measurements, the
‘‘IRMM-014’’ metallic iron standard was dissolved in 0.3 mol L1
HNO3 (Merck KGaA, Darmstadt, Germany). Before use, HNO3
was distilled until content in iron was o0.2 ppb (controlled by
ICP-OES).
Interference correction of 54Cr on 54Fe and 58Ni on 58Fe. To
avoid artifacts introduced by a high Cr or Ni corrections, Fe
isotope analyses with 54Cr/54Fe 4 0.1% were rejected, while
d58/56Fe values of samples with 58Ni/58Fe 4 10% were rejected
from the data sets (von Blanckenburg, submitted).17
2.3.2 ICP-OES. The total iron concentration in blood and
plasma was determined by validated inductively coupled
plasma optical emission spectroscopy (ICP-OES) on a Varian
Vista Pro system (Varian GmbH, Germany). The measurements
were carried out using a GMP method (Solvias AG, Basel,
Switzerland).
2.4 Data evaluation and equations used
Isotope ratio measurements by ICP-MS never yield absolute
ratios. They are aﬀected by a variable instrumental mass bias,
the degree of which depends on run conditions. To make the
measurements of unknown sample compositions compar-
able, a reference material of known composition is measured
(meas) before and after each sample. In this so-called ‘‘brack-
eting technique’’ sample ratios are normalized to the nominal
(nom) value of the reference material. We measured the
‘‘IRMM-014’’ iron reference standard before and after each
sample. The normalized 58Fe/56Fe ratio of the sample
58Fe/56Fesample then is:
58Fe

56Fesample ¼ 58Fe

56FeIRMM-014nom

58Fe

56Fesamplemeas
58Fe=56FeIRMM-014meas
(1)
As natural variations in the stable isotope composition of an
element are usually small, a more convenient reporting of
isotope ratios is conventional in Isotope Geochemistry. This
so-called delta (d) notation also accounts for diﬀerences in
instrumental mass bias, and is used for reporting relative
diﬀerences in iron isotope ratios between the sample and the
reference material. Accordingly, measured 58Fe/56Fe ratios are
reported as d58/56Fe values and usually multiplied by 1000 to
be reported in permil [%] or parts per thousand (1% = 0.1%)
according to eqn (1).
d58=56Fesample
%
¼
58Fe

56Fesample
58Fe=56FeIRMM-014
 1
 
 1000 (2)
We use eqn (1) throughout this paper, but for consistency we
also report the d58/56Fe values from eqn (2) in the Online
Supplement S4 (von Blanckenburg, submitted).17 By using
58Fe/54Fe isotope ratios for calculation, similar ferrokinetics
and absorption results are obtained.
The molar amount of absorbed [58Fe]SBR759-related iron
niso is calculated by eqn (3), derived from (Walczyk, 1997).
24
niso ¼ nnat 
a58nat  R58=56;sample  a58nat
R58=56;sample  a56iso  a58iso
(3)
nnat, the molar amount of iron of natural composition (calcu-
lated with Fe concentration (Feconc) in blood and the atomic
weight of natural iron (awtFe,nat) at baseline (t = 0 h)); a
58
nat, the
natural isotopic abundance of 58Fe at baseline; a56nat, the natural
isotopic abundance of 56Fe at baseline; a58iso, the isotopic abun-
dance of 58Fe in SBR759; a56iso, the isotopic abundance of
56Fe in
SBR759; R58/56,sample, the
58Fe/56Fe ratio relative to ‘‘IRMM-014’’
iron standard, calculated using eqn (1).
The atomic weight of iron of natural composition (awtFe,nat)
is calculated for each subject by eqn (4):
awtFe,nat = m54a54nat + m56a56nat + m57a57nat + m58a58nat (4)
m5x, the atomic weight of
5xFe (DeLaeter, 2003);31 a5xnat, the
natural abundance of 5xFe (x = 4, 6, 7 and 8) at baseline; The
latter is calculated by eqn (5) and (6):
a56nat ¼
1
1þ R54=56;nat þ R57=56;nat þ R58=56;nat (5)
a5xnat = a
56
natR5x/56,nat (6)
R5x/56,nat, the
5xFe/56Fe ratio relative to the ‘‘IRMM-014’’ iron
standard according to eqn (2), measured at baseline (x = 4, 7 and 8).
The abundances of the iron isotopes in SBR759 (a5xiso) are
calculated by eqn (7) and (8):
a56iso ¼
1
1þ R54=56;iso þ R57=56;iso þ R58=56;iso
(7)
a5xiso = a
56
isoR5x/56,iso (8)
R5x/56,iso, the
5xFe/56Fe ratio relative to the ‘‘IRMM-014’’ iron
standard according to eqn (2) of SBR759 (x = 4, 7 and 8).
The molar amount of absorbed [58Fe]SBR759-related iron
(niso) can be converted to the amount of adsorbed iron in mg
(miso) by eqn (9):
miso = nisoawtFe,iso1000 (9)
The atomic weight of iron in SBR759 (awtFe,iso) is calculated
by eqn (10):
awtFe,iso = m54a54iso + m56a56iso + m57a57iso + m58a58iso (10)
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Due to the long life span of erythrocytes (B120 days), the
total amount of absorbed [58Fe]SBR759-related iron can be
determined 14 days (or if more conservative 21 days) after the
administration. Since not all of the absorbed [58Fe]SBR759-
related iron is incorporated into erythrocytes, an incorporation
factor (finc) is included (Walczyk, 1997).
24 According to (Bernat,
1983),32 70–90% of absorbed [58Fe]SBR759-related iron is incor-
porated into erythrocytes. Therefore, finc will be set to the mean
value of 80%. The final, absolute amount of absorbed
[58Fe]SBR759-related iron mabs is calculated by eqn (11):
mabs ¼ miso
finc
(11)
We note that during intestinal absorption light isotopes
are preferred by mass-dependent isotope fractionation. For
European male omnivores this fractionation amounts to a shift
in the 58Fe/56Fe ratio by a factor of 0.9985 (von Blanckenburg,
2013).33 As this shift is negligible when compared to the shifts
in 58Fe/56Fe introduced by [58Fe]SBR759, we ignore this absorp-
tion eﬀect.
The blood volume (BV; in mL) is calculated by eqn (12)
(Geigy Scientific Tables, 1984)34 which is based on the body
length (L; in cm) and the body mass (B; in kg) (Table 1):
BV = L  28.5 + B  31.6  2820 (12)
The corresponding plasma volume is calculated by multi-
plying the calculated blood volume BV with the blood/plasma
volume ratio of 0.5769 calculated from Table II in (Davies,
1993).35
3 Results and discussion
3.1 Safety of subjects and drug tolerability assessment
Doses of 12 g 58Fe-labeled SBR759, divided in three doses of 4 g,
each, and administered with a low phosphorus meal, were
generally well tolerated by healthy male subjects. There was no
serious adverse event reported in the study. The most common
adverse events were flatulence, discolored feces, diarrhea, and
headache which were mild or moderate and transient. There
were no clinically significant changes in laboratory parameters,
vital signs, ECGs, or physical examinations over the course of the
study. There was no sign of overt or acute iron toxicity as there
were no clinically significant changes in laboratory parameters
hemoglobin, hematocrit, ferritin and transferrin saturation
(TSAT) (Table 3).
The mean TSAT values at Days-1, 11 and 21 were 35.8, 24.3
and 24.0% which were in the normal range (16–45%) and
distinctly below the toxic limit of 85% leading to labile redox
active plasma iron (LPI). It should be noted that an obvious
TSAT outlier of 93.6% at baseline (prior to treatment) was
reported for subject 5110. This value was not repeated nor
excluded from the listing. There was no impact on the mean
versus median values, therefore mean values are reported.
There was a trend to numerically lower mean and median
hemoglobin, hematocrit, ferritin and TSAT values. These trends
were likely due to the volume of blood drawn from subjects in
the immediate post dose time period (B246 mL) which
amounts to B108 mg of iron lost during the first 26 hours of
the study andB132 mg iron during the entire study (300 mL 
Hct  1 mg mL1). These losses occurred in the time period
after dosing. Hence they are not expected to drive iron absorp-
tion as it is expected that the 58Fe-isotope-labeled-SBR759
would have passed through the proximal small bowel before
the blood/iron losses would have stimulated the need to iron
absorption. Therefore this is not expected to have an impact on
the conclusion of iron absorption from SBR759.
These safety results in healthy volunteers are in agreement with
those of three clinical trials in chronic kidney disease patients on
hemodialysis (Block, 2010)9 (Chen, 2011)10 (Fukagawa, 2014)11
where SBR759 was well tolerated within the anticipated clinical
dose range of 3.75 to 15 g SBR759 per day. No treatment-related
serious adverse events were observed nor were there clinically
relevant changes in iron indices.
3.2 Ferrokinetics in blood and plasma
The ferrokinetics of SBR759-related iron in whole body blood of
the individual subjects was investigated in the time period from
1 to 21 days (0–490 h) post [58Fe]SBR759 dose (Fig. 1).
In order to monitor the rapid systemic uptake of
[58Fe]SBR759-related iron into the bloodstream, also whole
body blood and plasma in the early time window between 0
and 26 hours were investigated (Fig. 2A and B).
The calculation of total blood iron and plasma iron was based
on 58Fe/56Fe isotope ratios. In contrast to blood, plasma 58Fe/56Fe
and 58Fe/54Fe ratio values were very high due to the 320- to 590-fold
lower amount of iron in plasma (adult males: 0.75–1.75 mg L1)
(Geigy Scientific Tables, 1984).34 Within 0–26 h, most subjects
reached a first maximum at 12 hours amounting to 0.22 to 2.3 mg
Fig. 1 Amount of total [58Fe]SBR759-related iron in whole body blood
collected between Day 1 and Day 21 post 12 g (3  4 g) of [58Fe]SBR759
dose to 12 healthy male subjects. The amount of total blood iron was
determined by MC-ICP-MS. Total blood iron calculation based on 58Fe/56Fe
isotope ratios. The time window between 0 and 26 hours (dashed rectangle)
is shown enlarged in Fig. 2A. Almost identical total blood iron values were
calculated by using 58Fe/54Fe isotope ratios (not shown).
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in blood (Fig. 2A) and 0.15 to 1.8 mg in plasma (Fig. 2B). There-
after, total blood and plasma iron values dropped by about
26 hours to low levels of 0.01–0.22 mg in blood and 0.02 to
0.18 mg in plasma. Comparable to our study, healthy volunteers
treated with oral phosphate binders combined with supplemental
iron salts reached plasma iron plateaus by about 6 hours following
dosing (Pruchnicki, 2002).36 In our study the ferrokinetic curves
were formed out of three single curves related to each of the three
consecutive [58Fe]SBR759 doses given at 0, 4 and 10 hours. The
early maximum at approx. 12 hours can be attributed to a transient
appearance of transferrin-bound SBR759-related iron in blood and
plasma. After 26 hours, SBR759-related total blood iron steadily
increased, each subject reaching a different plateau between 14
and 21 days (Fig. 1). Total SBR759-related blood iron ranged
between 3.03 and 11.1 mg revealing high inter-subject variability
(CV: 41–104%).
Apart from the upstream intestinal enterocytes, blood plasma
is the primary central compartment for iron absorption since
virtually all cells in the organism take up iron from transferrin
(the major iron transporter protein: apo-transferrin containing
bound iron) (Walczyk, 2005).16 Iron transport-capacity of trans-
ferrin is limited and transferrin-bound iron turnover is relatively
short-lived due to the quick transfer of freshly absorbed iron to
other tissue compartments, i.e., mainly to the bone marrow for
erythrocyte synthesis but also to liver and muscle tissues.
3.3 Extent of systemic iron absorption
The absorption of [58Fe]SBR759-related iron was investigated in
blood samples collected at baseline and compared to those
measured 14 and 21 days after administration (Table 4) (Fig. 1).
Total blood iron was measured by MC-ICP-MS and applying
the stable isotope dilution principle. Assuming that approx.
80% of absorbed SBR759-related iron is incorporated into
erythrocytes (Bernat, 1983),32 the amount of absorbed iron
ranged from 3.8 mg (subject 5109) to 13.9 mg (subject 5101)
at Day 21 following [58Fe]SBR759 administration. The arith-
metic mean was 7.8 mg which corresponds to about 0.3% of the
iron dose in SBR759. Compared to the daily iron uptake of 1 to
2 mg in healthy male adults, a mean uptake of 7.8 mg appears
to be relatively high. An extrapolation of these data to the target
CKD patient population is tainted with uncertainties because in
contrast to healthy subjects, CKD patients do not absorb orally
administered iron salts well (Ho¨rl, 2007).37
In a recent iron absorption study (Geisser, 2010)38 with 10 g
59Fe-radiolabeled PA21 (an iron-based polynuclear iron(III)
oxy-hydroxide compound), which was administered to CKD
patients and healthy volunteers (HVs), the HVs have taken up
8.3 mg iron, and CKD patients 10-fold less (B0.8 mg). This
malabsorption has been linked to the inflammatory state
associated with CKD and up-regulation of hepcidin expression
Fig. 2 Amount of total [58Fe]SBR759-related iron in whole blood (A) and
plasma (B) during the early time period 0–26 hours post 3  4 g
[58Fe]SBR759 dose to 12 healthy male subjects. The amount of iron in
blood and plasma in individual subjects (inset: average  SEM in blood and
plasma over n = 12 subjects) was determined by MC-ICP-MS. Amount of
iron calculation based on 58Fe/56Fe isotope ratios. Almost identical total
blood and plasma iron values were calculated by using 58Fe/54Fe isotope
ratios (not shown).
Table 4 Calculated amounts of systemically absorbed iron in whole
blood of healthy male subjects measured at Days 14 and 21 following oral
dosing of 12 g (3  4 g) of [58Fe]SBR759
Subject
Blood collected
after 14 days
Blood collected
after 21 days
Calculated amount
of absorbed iron
Calculated amount
of absorbed iron
Absolute
value
(mg)
Relative to
total iron
dose (%)
Absolute
value
(mg)
Relative to
total iron
dose (%)
5101 13.4 0.53 13.9 0.54
5102 6.8 0.27 7.3 0.29
5103 11.5 0.45 11.8 0.46
5104 6.8 0.27 7.3 0.28
5105 7.0 0.27 7.3 0.28
5106 3.8 0.15 4.1 0.16
5107 8.2 0.33 8.7 0.34
5108 4.3 0.17 4.4 0.17
5109 3.5 0.14 3.8 0.15
5110 9.8 0.39 10.4 0.41
5111 4.7 0.18 5.0 0.20
5112 8.7 0.34 9.2 0.36
Arithmetic mean 7.4 0.29 7.8 0.30
Median 6.9 0.27 7.3 0.29
Minimum 3.5 0.14 3.8 0.15
Maximum 13.4 0.53 13.9 0.54
First quartile (25%) 4.6 0.18 4.9 0.19
Third quartile (75%) 9.0 0.35 9.5 0.37
Standard deviation 3.1 0.12 3.2 0.12
CV (%) 42 41 41 40
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(Ho¨rl, 2007)37 (Andrews, 2007).39 Although there is a hypothe-
tical risk for local toxicity of SBR759 with chronic administra-
tion, the assessment of such a risk is out of scope for this
abbreviated trial and is a more appropriate question for chronic
toxicology studies in animals and additional clinical testing
in the target patient population which would be required prior
to health authority approval (Block, 2010)9 (Chen, 2011)10
(Fukagawa, 2014).11 In addition, considering the low bioavail-
ability of iron from the SBR759 drug substance compared to
that expected from therapeutic oral iron supplements (e.g.
ferrous sulfate) which are administered by thousands of
patients per day, the risk of ROS-related GIT damage appears
to be minimal.
4 Conclusions
 The results of this phase I mechanistic iron uptake study
provide insight into the potential for iron absorption from a
daily dose of 12 g (divided in 3  4 g) of [58Fe]SBR759 to healthy
male subjects.
 The study demonstrated absorption of 0.15 to 0.54% of the
total daily administration of [58Fe]SBR759-related iron which
amounted on average to 7.8 mg; approx. 5-fold more than the
basal daily iron absorption (1 to 2 mg).
 [58Fe]SBR759-related iron transiently appeared in blood
and plasma within the first 26 hours post first dose, followed by
second later phase in blood ranging over 3 weeks which is
characterized by redistribution of [58Fe]SBR759-related iron
from blood into other relevant iron storage tissue compart-
ments such as bone marrow, liver and muscle.
 In an interdisciplinary collaboration of the pharmaceutical
industry with the academic environment in the field of Geo-
sciences, the MC-ICP-MS technique was successfully applied for
reliably measuring iron absorption and ferrokinetics in human
blood and plasma with high specificity, sensitivity, accuracy
and precision.
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